Cargando…

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer

The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Na, Sun, Pan, Jin, Haizhen, Yang, Yuqin, Zhao, Qingya, Zhou, Lin, Guo, Lili, Yang, Xiaohua, Lu, Liming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Preclinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365669/ https://www.ncbi.nlm.nih.gov/pubmed/32701251 http://dx.doi.org/10.1097/CAD.0000000000000935

Ejemplares similares

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2016)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Acute Kidney Injury Results in Long-Term Diastolic Dysfunction That Is Prevented by Histone Deacetylase Inhibition
por: Soranno, Danielle E., et al.
Publicado: (2021)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo
por: Song, Gaojie, et al.
Publicado: (2022)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
por: Yao, Yushi, et al.
Publicado: (2013)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
por: Chen, Jane Y., et al.
Publicado: (2013)

Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner
por: Yuan, Xiang-Gui, et al.
Publicado: (2019)

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2018)

The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF-κB pathway in multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2019)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL
por: Wei, Chong, et al.
Publicado: (2021)

Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits
por: Chowdhury, Mohammed M., et al.
Publicado: (2020)

Can Paclitaxel Coated Balloons Have a Deep Impact on Critical Limb Ischemia?
por: Parikh, Sahil A., et al.
Publicado: (2021)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
por: Asaduzzaman, Muhammad, et al.
Publicado: (2017)

Downstream Paclitaxel Released Following Drug-Coated Balloon Inflation and Distal Limb Wound Healing in Swine
por: Granada, Juan F., et al.
Publicado: (2021)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

Reversible histone deacetylase activity catalyzes lysine acylation
por: Tsusaka, Takeshi, et al.
Publicado: (2023)

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2022)

Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer
por: Zhang, Xiaoyi, et al.
Publicado: (2022)

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
por: Wen, Tingyu, et al.
Publicado: (2022)

S-Adenosyl-l-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells
por: Liu, Tsang-Pai, et al.
Publicado: (2015)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
por: Cao, Lixia, et al.
Publicado: (2021)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways
por: Johnstone, Andrea L., et al.
Publicado: (2019)

High-Fat Diet Enhances Neutrophil Adhesion in LDLR-Null Mice Via Hypercitrullination of Histone H3
por: Osaka, Mizuko, et al.
Publicado: (2021)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy
por: Ruttala, Hima Bindu, et al.
Publicado: (2017)

Cardiac-Directed Expression of Adenylyl Cyclase Catalytic Domain Reverses Cardiac Dysfunction Caused by Sustained Beta-Adrenergic Receptor Stimulation
por: Gao, Mei Hua, et al.
Publicado: (2016)

Nicotine‐induced neuroplasticity in striatum is subregion‐specific and reversed by motor training on the rotarod
por: Licheri, Valentina, et al.
Publicado: (2019)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9elfvjspuea3n9eei6op25061s